INFLIXIMAB TREATMENT
Regulation of peripheral classical and non classical monocytes on infliximab treatment in patients with rheumatoid arthritis and ankylosing spondylitis
... on infliximab treatment Serum levels of the corresponding cytokines (SDF-1 and MCP-1) at different time points were measured concomi- tantly in either patient group before and on in fl iximab ...iximab ...
5
Predictors of infusion reactions during infliximab treatment in patients with arthritis
... during infliximab treatment in both RA and SpA patients ...during treatment with disease-modifying antirheumatic drugs (DMARDs) ...Also, treatment with tumour necrosis factor blockers has been ...
7
Low infliximab serum trough levels and anti infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
... of infliximab treatment in RA patients, next to the initiation phase ...be infliximab serum trough levels and anti-infliximab antibody ...of infliximab could be carefully dose reduced, ...
6
The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases
... effective treatment may lead to permanent loss of physical function, reduced productivity, and increased rates of work disability about 10 years after disease onset ...of treatment with infliximab on ...
6
Autoantibody profile in rheumatoid arthritis during long term infliximab treatment
... after treatment with inf- liximab plus methotrexate, and even higher figures were reported in patients with ankylosing spondylitis who were treated with slightly higher infliximab doses without meth- ...
9
Mass spectrometry based analysis of cerebrospinal fluid from arthritis patients—immune related candidate proteins affected by TNF blocking treatment
... as infliximab and TNFα do not readily pass the blood-brain barrier (BBB); how- ever, there is a saturable receptor-assisted transport sys- tem for TNFα across the BBB ...the infliximab antibody were ...
11
Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab
... of infliximab treat- ment in most patients with active AS has recently been demonstrated by an open-labeled multicenter study which described a statistical improvement in the ASAS criteria in ...that ...
8
Original Article Matrix metalloproteinase-3 and -9: possible biomarkers of infliximab efficacy in ankylosing spondylitis (AS)?
... during infliximab treatment and to evaluate whether MMP-3 and MMP-9 were associated with clinical measures of disease activity and function in ...of infliximab treatment in 44 AS ...with ...
9
Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment
... of treatment, another PAXgene tube was ...of treatment, clinical response was assessed using the European League Against Rheumatism (EULAR) response criteria ...
10
Circulating tumour necrosis factor α bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response
... received infliximab according to the ATTRACT (Anti-TNF Trial in RA with Concomitant Therapy) protocol at 3 mg/kg every 8 weeks, combined with meth- otrexate ...before infliximab therapy in all patients (n = ...
7
Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behçet’s disease: a large scale, long term postmarketing surveillance in Japan
... Results: Among the 656 patients evaluated for safety, 555 (84.6%) completed the 24-month study period. The incidence of adverse drug reactions (ADRs) and serious ADRs were 32.32% and 6.10%, respectively, and the safety ...
12
How does infliximab work in rheumatoid arthritis?
... following infliximab treatment was shown in an early study to be associated with a reduction in the cellularity of the synovium of RA patients ...ing infliximab therapy (Figure 4) ...
7
Resection of a methicillin resistant Staphylococcus aureus liver abscess in a patient with Crohn’s disease under infliximab treatment: a case report
... undergoing infliximab treat- ment for Crohn ’ s disease was admitted to our hospital with high fever and pain in the right upper abdominal ...underwent infliximab treatment two years before the ...
5
Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two year prospective study
... the treatment of RA with infliximab were of IgM ...during infliximab treatment might be the consequence of a higher production of natural autoreactive IgM, but might also be an induced ...
9
Infliximab: 12 years of experience
... of treatment, infl iximab plus MTX prevented the progressive joint damage associated with infl ammation and resulted in a signifi cant reduction in progression of radiological changes, using the modifi ed van der ...
18
Infliximab Therapy in Iraqi Patients with Moderate to Severe Psoriasis
... Pruritus was recorded in 2 patients, boils were reported in 1 patient, both were disappeared with continuation of treatment. Alopecia are at a developed in one patient. Four patients had infusion reaction, only in ...
8
Seven year follow up of infliximab therapy in rheumatoid arthritis patients with severe long standing refractory disease: attrition rate and evolution of disease activity
... Initiated between 2000 and 2001, the Belgian expanded access program (EAP) cohort is among the largest of that time, including 511 RA patients treated with infliximab therapy. The majority of these patients ...
8
A randomized controlled trial comparing PF 06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy
... The availability of biosimilars may expand access to bio- logic therapies such as infliximab, providing patients with additional safe and efficacious treatment options. Regulatory approval for biosimilars ...
13
Aspects of early arthritis Traditional DMARD therapy: is it sufficient?
... and treatment paradigms for rheumatoid arthritis (RA) and other potentially destructive arthritides have changed over recent ...delaying treatment, especially in high(er) risk patients, or inadequate ...
6
Clinical response to discontinuation of anti TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
... further treatment with anti-tumor-necrosis ...the treatment. Retreatment with infliximab was safe and resulted in clinical improvement in all patients to a state similar to that before the ...
6